FDA Quality Management System Regulation Alignment with ISO 13485 (2026): A Wake-Up Call for AI-Enabled Device Buyers and Their Evidence Expectations
The US FDA’s quality management system regulation is about to align with the international standard ISO 13485, effective as of 2026. This change poses a significant risk to organisations buying or deploying AI-enabled medical devices in regulated sectors such as healthcare, insurance, and financial services – particularly those operating in Canada and the UK.
What is happening?
The FDA’s quality management system regulation will shift from a performance-oriented approach to a more risk-based approach aligned with ISO 13485. This new standard focuses on the design of quality into products, rather than just testing them after production. As a result, AI-enabled medical device buyers must now ensure that devices meet this higher standard for quality and safety.
Why it demands action now?
The alignment of FDA regulations with ISO 13485 increases organisational exposure in three critical areas:
1. Capability risk: Devices must be designed to operate safely and effectively; their performance cannot solely rely on testing after production.
2. Governance risk: Organisations must demonstrate compliance with the new standard, providing a clear audit trail for regulatory bodies and boards of directors.
3. Liability risk: Companies may face liability claims if they deploy devices that do not meet the standards, and are unable to defend these decisions when questioned by regulatory agencies or courts.
The action:
Organisations should take immediate steps to address these risks by implementing a quality management system aligned with ISO 13485. This involves a comprehensive review of existing processes and systems, followed by the design and implementation of new procedures that meet the standard’s requirements. Timeframes for this will depend on the complexity of the devices involved and the size of the organisation.
How Straven & Co helps:
Straven & Co offers independent validation services to ensure AI-enabled medical device buyers make informed decisions before committing resources or deploying devices into production. Our expert team examines AI claims against an organisation’s operations, people, governance and legal exposure, as well as vendor claims, delivering a plain verdict: proceed, proceed with conditions, or do not. This unbiased assessment protects clients from costly failures by providing transparent evidence of the device’s capabilities and limitations.
Straven & Co examines AI decisions before they are acted on: stravenandco.com